All In Biotech

Drug Trial Radar · NCT03158948

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM in Patients With Septic Shock. A Randomised, Double-blind, Two-Stage, Placebo Controlled Study

Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

50

Actual

Start

Jul 3, 2017

Primary completion

Jun 13, 2018

Study completion Jun 13, 2018

Sponsor

Lead sponsor
InotremIndustry
Sponsor type
Industry
First posted
May 18, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomised, double-blind, two-stage, placebo controlled study. It is designed to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of 3 doses of nangibotide versus placebo in adult patients with septic shock.

Conditions

  • Shock, Septic

Interventions

  • Nangibotide 0.3 mg/kgDrug

    Formulated LR12 peptide

  • PlaceboDrug

    placebo

  • Nangibotide 1 mg/kgDrug

    Formulated LR12 peptide

  • Nangibotide 3 mg/kgDrug

    Formulated LR12 peptide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Patients Experiencing Treatment Emergent Adverse Events From Screening Until Study CompletionTime frame: Adverse events experienced until D28 (End of study visit)
  2. Systolic Blood Pressure (SBP)Time frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5) and on final study day at day 28 (D28).
  3. Diastolic Blood Pressure (DBP)Time frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5) and on final study day at day 28 (D28).
  4. Median Arterial Pressure (MAP)Time frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5) and on final study day at day 28 (D28).
  5. Heart RateTime frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5).
  6. TemperatureTime frame: Vital signs were assessed each day from day zero (D0 [before investigational medicinal product initiation]) to end of infusion at day 5 (D5).
  7. ElectrocardiogramTime frame: Electrocardiogram was performed each day from D0 (before IMP initiation) to D5 (EOI) and on D28 (EOS).
  8. Anti-Drug Antibodies (ADA Dimer)Time frame: Anti-Drug Antibodies test were done at D0, D10 and D28 in all patients.
  9. Anti-Drug Antibodies (ADA Monomer)Time frame: Anti-Drug Antibodies test were measured at D0, D10 and D28.

Locations

4 sites in 4 countries. Site status is shown where the registry gives one.

  • Cliniques Universitaires Saint-Luc (there may be other sites in this country)

    Brussels, Belgium

  • Inserm Clinical Investigational Center, CHU Dupuytren (there may be other sites in this country)

    Limoges, France

  • Radboudumc (there may be other sites in this country)

    Nijmegen, Netherlands

  • Hospital Clínico San Carlos, Medicina Intensiva (there may be other sites in this country)

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.